Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activations

Three investigational new drug trials were recently activated -- Canadian Cancer Trials Group IND.193, IND.209, and IND.210.

Canadian Cancer Trials Group IND.193 -- A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia -- was centrally activated June 21, 2012.


Canadian Cancer Trials Group IND.209 -- A Randomized Phase II Study of Reolysin in Combination with Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients with Metastatic Castration Resistant Prostate Cancer -- was centrally activated June 11, 2012.


Canadian Cancer Trials Group IND.210 -- A Randomized Phase II Study of Reolysin in Combination with FOLFOX6/Bevacizumab or FOLFOX6/Bevacizumab Alone in Patients with Metastatic Colorectal Cancer -- was centrally activated June 11, 2012.